Recombinant Human Uncharacterized aarF domain-containing protein kinase 5 (ADCK5)

What experimental strategies confirm ADCK5’s kinase activity and substrate specificity?

To validate ADCK5’s predicted serine/threonine kinase function, researchers should implement a three-phase approach:

• In vitro kinase assays: Incubate purified recombinant ADCK5 with synthetic peptides containing serine, threonine, or tyrosine residues under ATP-rich conditions. Use radioactive γ-32P-ATP or anti-phosphoantibodies for phosphorylation detection .

• Mass spectrometry-based substrate screening: Combine ADCK5 with tissue lysates (e.g., lung or duodenum ) followed by phosphoproteomic analysis to identify natural substrates .

• Structural validation: Perform X-ray crystallography or cryo-EM to resolve the ATP-binding pocket conformation and catalytic loop geometry .

Table 1: Key parameters for kinase activity assays

How does ADCK5 tissue expression variability impact functional studies?

ADCK5 displays differential expression across tissues, with highest levels observed in the duodenum (FPKM 15.7) versus moderate expression in lung (FPKM 8.3) . Researchers must:

• Normalize cellular models: Use intestinal organoids or lung adenocarcinoma lines (e.g., A549) for pathophysiological relevance

• Control for isoform diversity: Perform RT-PCR with exon-spanning primers to detect alternative splicing variants

• Correlate expression with activity: Quantify kinase activity per µg protein across tissue lysates using standardized protocols

What computational and experimental approaches resolve ADCK5’s structure-function paradoxes?

Despite sequence homology to atypical kinase family members, ADCK5 lacks conserved catalytic residues in 38% of kinase subdomains . Address this through:

Integrative molecular modeling

• Build homology models using Phyre2 with ADCK3 (template 4WNU) as reference

• Perform molecular dynamics simulations (200 ns trajectories) to assess ATP-binding stability

• Validate critical residues (e.g., Lys-209 in β3 sheet) via site-directed mutagenesis

Experimental validation workflow:

• Clone ADCK5 mutants (K209A, D227N) into baculovirus vectors

• Compare wild-type vs mutant kinase activity in HEK293T overexpression systems

• Analyze structural impacts via circular dichroism spectroscopy

How can phosphoproteomic data reconcile contradictory reports on ADCK5 signaling roles?

Recent studies propose ADCK5 involvement in both ERK5-mediated senescence and Wnt/β-catenin pathways , creating mechanistic ambiguity. A multi-omics strategy is essential:

• Time-resolved phosphoproteomics: Treat ADCK5-knockout cells with serum growth factors, collecting samples at 0/15/60/240 min for LC-MS/MS analysis

• Pathway enrichment analysis: Map phosphorylated substrates to KEGG pathways using STRING-db (FDR <0.05)

• Functional validation: CRISPRi knockdown of top candidate substrates (e.g., MAPK12) followed by senescence-associated β-galactosidase assays

Table 2: Conflicting ADCK5 pathway associations

What orthogonal methods validate ADCK5’s therapeutic potential in lung cancer?

While preliminary data suggest ADCK5 overexpression correlates with NSCLC progression , rigorous validation requires:

Preclinical candidate assessment

• Genetic dependency screens: Perform shRNA dropout assays in 50+ lung cancer lines (Broad Institute DepMap)

• Chemical probe development: Screen 10,000-compound libraries against recombinant ADCK5 using HTRF kinase assays

• In vivo modeling: Generate conditional ADCK5 knockout mice crossed with KRASG12D lung adenocarcinoma models

Key validation metrics:

• Tumor burden reduction ≥40% in knockout vs wild-type

• IC50 shift <2-fold in isogenic cell pairs with ADCK5 overexpression

• Phospho-substrate signature replication in patient-derived xenografts

Addressing the kinase activity controversy

The central dispute stems from conflicting reports on ADCK5’s catalytic competence . A recommended resolution pathway includes:

• Standardized activity assays:

  • Consensus buffer: 20 mM HEPES (pH 7.4), 10 mM MgCl2, 1 mM DTT

  • Positive control: Active MAPK7 (ERK5) at 100 nM concentration

  • Negative control: Heat-denatured ADCK5 (65°C, 10 min)

• Phosphoacceptor scanning: Synthesize peptide arrays with systematic Ser→Ala substitutions to identify essential residues

• Collaborative validation: Establish multi-lab reproducibility studies through CASP kinase challenge initiatives